Physician profile
Blen D Daniel
NPI 1285286492
$12,324.39
in general payments reported to CMS, 2019-2025
33 companies · $3,228 in 2025
The $3,228 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,063 · 2022: $2,151 · 2023: $2,740 · 2024: $3,142 · 2025: $3,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,848 · Consulting Fee: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,848.23 |
| Consulting Fee | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,440.30 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Abbott Laboratories | $1,367.57 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $1,324.34 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $891.75 | 2022-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.77 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $749.66 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $652.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $638.80 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $586.93 | 2021-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $504.31 | 2021-2024 | |
| Cvrx, INC. | $501.93 | 2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $484.85 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $337.63 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $266.48 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $229.60 | 2025 | Attruby |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $187.67 | 2023-2024 | Krystexxa, Repatha |
| Lexicon Pharmaceuticals, INC. | $148.34 | 2023-2024 | Inpefa |
| Genzyme Corporation | $147.99 | 2025 | |
| Scpharmaceuticals INC. | $142.61 | 2023-2025 | |
| Edwards Lifesciences Corporation | $131.16 | 2024 | Sapien 3 Ultra Resilia |
| Itamar Medical INC | $130.10 | 2021-2023 | Watchpatone |
| Zoll Respicardia, INC. | $109.66 | 2023 | Remede System |
| Atricure, INC. | $92.79 | 2022 | |
| Abiomed | $88.10 | 2023 | Impella |
| Procyrion, INC. | $86.42 | 2024 | |
| United Therapeutics Corporation | $80.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $30.42 | 2021 | |
| Impulse Dynamics (USA) INC. | $28.07 | 2023 | Optimizer |
| Analog Devices INC. | $25.82 | 2025 | Sensinel Cpm Wearable |
| Azurity Pharmaceuticals, INC. | $22.99 | 2025 | Edarbyclor |
| Amarin Pharma, INC. | $21.00 | 2021 | |
| Vifor Pharma, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blen Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.